Insulin B chain-reactive CD4+ T cell (Insulin B-reactive CD4+ T cell)

Insulin B chain-reactive CD4+ T cells are a specialized subset of T lymphocytes that play a central role in the autoimmune destruction of pancreatic beta cells in Type 1 Diabetes (T1D). These cells possess T-cell receptors (TCRs) that specifically recognize epitopes from the insulin B chain, most notably the B:9-23 sequence, when presented by MHC class II molecules like HLA-DQ8 or HLA-DR4 (Nakayama et al., Nature, 2005; Michels et al., Journal of Immunology, 2011). In healthy individuals, these autoreactive cells are typically deleted or suppressed, but in T1D patients, they become activated and infiltrate the pancreatic islets. Once active, they secrete pro-inflammatory cytokines and provide essential help to B cells and CD8+ T cells, driving the progression of the disease (Pathiraja et al., Diabetes, 2015). Therapeutic strategies targeting these cells focus on antigen-specific immunotherapy (ASIT) to restore immune tolerance. This involves the administration of insulin-derived peptides or DNA vaccines, such as NNC0361-0027, to induce anergy or promote the differentiation of protective regulatory T cells (Tregs) (ClinicalTrials.gov, NCT03895437). By specifically targeting the insulin-reactive population, these therapies aim to halt beta-cell destruction without the risks associated with broad systemic immunosuppression. However, challenges remain, including the risk of inducing anaphylaxis or transiently exacerbating the autoimmune response during treatment.

Other names

Insulin-specific CD4+ T cellInsulin B:9-23 reactive T cellProinsulin-reactive CD4+ T cellAutoreactive insulin-specific T lymphocyte

Antigen-specific immune tolerance induction via anergy, deletion, or regulatory T cell (Treg) induction.